Table 2 Outcomes in published leterature for SBRT for Liver metastasis
Study | Number of lesions | Number of patients | Primary | Dose/fractionation | Toxicity | Median follow Up (Months) | Local control | Survival |
|---|---|---|---|---|---|---|---|---|
Blomgren et al. [24] | Variable | 31 | Mixed | 8-66Gy/1–4 | 2 Hemorrhagic Gastritis | 1.5–3.8 | 80% | NR |
Herfarth et al. [25] | 1–3 | 37 | NR | 14–26 Gy/1 | NR | Mean 14.9 | 18 m:67% | 1 yr.:76% 2 yr.:55% |
Hoyer et al. [26] | 1–6 (< 6 cm) | 44 | Mixed Majority CRC | 45Gy/3 | 1 Liver Failure 2 severe late GI | 52 | 2 yr.: 86% | 1 yr.:67 2 yr.:38 |
Mendez Romero et al. [27] | 1–3 < 7 cm) | 25 | Mixed Majority CRC | 37.5Gy/3 | 4 acute Grade ≥ 3 1 late Grade 3 | 12.9 | 2 yr.: 86% | 1 yr.:85% 2 yr.:62% |
Rusthoven et al. [29] | 1–3 (< 6 cm) | 47 | Mixed Majority CRC | 60Gy/3 | < 2% Late Grade ≥ 3 | 16 | 2 yr. 92% < 3 cm:100% | Median 17.6 |
Lee et al. [30] | Variable | 68 | Mixed Majority CRC | 28-60Gy/3 | 8 acute Grade 3 1 Grade 4 | 10.8 | 1 yr.: 71% | 18 m:47% |
Ambrosino et al. [37] | 1–3 (< 6 cm) | 27 | Mixed Majority CRC | 25-60Gy/3 | NR | 13 | 74% | NR |
Goodman et al. [23] | 1–5 (< 5 cm) | 26 | Mixed Majority CRC | 18-30Gy/1 | 4 late Grade 2 | 17.3 | 1 yr.:77% | 1 yr.:62% 2 yr.:49% |
Rule et al. [31] | 1–5 | 27 | Mixed Majority CRC | 30Gy/3 50-60Gy/5 | No ≥ Grade 2 | 20 | 30Gy56% 50Gy:89% 60Gy:100% | 30Gy56% 2 yr. 50Gy:67% 2 yr. 60Gy:50% 2 yr |
Scorsetti et al. [39] | 1–3 (< 6 cm) | 61 | Mixed Majority CRC | 52.5–75/3 | No ≥ Grade 3 | 24 | 91% | 1 yr.: 80% 2 yr.:70% |
Present Study | Variable | 427 | Mixed Majority CRC | 45(12–60)/3(1–5 | NR | 14(1–91) | Median:52 m 1 yr.: 84% 2 yr.:72% | Median:22 m 1 yr.: 74% 2 yr.:49% |